Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Dec 2;12:795741. doi: 10.3389/fimmu.2021.795741

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Lin, Chen, Chen, Lee and Wu

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Antibody responses elicited by Ad-S glycan-masking mutants against SARS-CoV-2 Beta (B.1.351) variant. (A) antisera for anti-S1 IgG titers from each group of mice (n=5) and tested individually in the first set of immunizations; (B) antisera for anti-RBD IgG titers from each group of mice (n=5) and tested individually in the first set of immunization experiments; (C) the dose-response pseudo-neutralization curves for the pooled sera of each immunized group of mice (n=5) and measured in triplicate for the first set of immunization experiments; (D) IC-50 NT titer for neutralizing antibodies against Beta (B.1.351 variant) for the first set of immunization experiments; (E) antisera for anti-S1 IgG titers from each group of mice (n=5) and tested individually in the second set of immunizations; (F) antisera for anti-RBD IgG titers from each group of mice (n=5) and tested individually in the second set of immunization experiments; (G) the dose-response pseudo-neutralization curves for the pooled sera of each immunized group of mice (n=5) and measured in triplicate for the second set of immunization experiments; (H) IC-50 NT titer for neutralizing antibodies against Beta (B.1.351 variant) for the first set of immunization experiments. Fold-changes of the Ad-S glycan-masking mutant IC-50 NT titer against the wild-type Ad-S (Beta, B.1.351 variant) titer are indicated. Statistical tests for multiple comparison of anti-S1 and anti-RBD IgG titers among Ad-s immunization groups were performed using the nonparametric test with Kruskal-Wallis with corrected Dunn’s multiple comparison. The statistical significance is expressed as follows: *p < 0.05 and **p < 0.01. Neutralization curves were fitted based on the equation of nonlinear regression log (inhibitor) vs. normalized response – variable slope using GraphPad Prism v6.01. The IC-50 values of neutralization were obtained from the fitting curves using GraphPad Prism v6.01. Error bars are plotted as standard deviation from the mean value. Not detectable for N.D.